Author Archives: Pascal Winnen

Cellestia Biotech raises CHF 20 million

Basel, 2018-12-19 – Cellestia Biotech AG successfully closes Series A financing round, raising a total of CHF 20 million. Melissa Kay Epstein elected to Board of Directors. Financing round led by FC Capital, Shanghai; PPF / Sotio, Prague; ETP Ventures, Boston & Beijing and significant investments by existing and new private investors Funds will be […]

Scailyte raises CHF 2.75M in seed funding and gains Swisscom Ventures & Zürcher Kantonalbank as investors

Scailyte AG, a Swiss startup in the emerging and rapidly growing field of single-cell technologies, raised CHF 2.75M in seed funding and gained Swisscom Ventures as a strategic investor. Zürcher Kantonalbank also joined the financing round, alongside the existing shareholders, thus reaffirming their trust in the competence and vision of Scailyte’s team. Dominique Megret, Head […]

Artidis: Cancer diagnosis in less than 3 hours

Marija Plodinec, CEO of Artidis (Img: Technologiepark Basel) “Artidis is based on the oldest diagnostic test on earth: palpation,” says Marija Plodinec, CEO and co-founder of Artidis AG. “In a nutshell, we palpate tissue on a molecular level,“ she adds with a twinkle. That’s because instead of a physician’s hand, Artidis runs a fine, high-precision […]

Resistell Closes Seed Round to Develop Faster Antibiotic Tests

Press release: Resistell AG closes seed round Resistell AG has today closed an oversubscribed seed financing round. Lead Investor Occident Group AG, Hemex AG and six other private investors invested in the EPFL spin-off developing the world’s fastest phenotypic antibiotic susceptibility test. 700,000 people die each year due to drug resistant infections. Unless we can […]

PHOENIX Award for PhagoMed

Award for phage therapy PhagoMed wins Austrian Entrepreneurship Award Phönix Vienna, 4 December 2018: Vienna-based Biotech company PhagoMed Biopharma GmbH was yesterday awarded the Austrian Entrepreneurship Award Phönix 2018 in the category “Start-Up International”. The Phoenix award honours the development of antibiotics alternatives based on phages, a class of natural viruses that only infect bacteria, […]

MassChallenge bestows CHF 500’000 CHF on eight startups

Yesterday, more than 450 people gathered to celebrate the winners of the MassChallenge Switzerland 2018 program. Eight startups received a sum of 500k in a zero-equity cash prize. The diamond winner, Scailyte received the highest share of the cash. The journey of the MassChallenge Switzerland program began four months ago with 51 startups from 30 countries. The […]

Scailyte wins Start JLM competition

Scailyte develops artificial intelligence technology to enable precision medicine and early detection of complex diseases. The company has won the Start JLM competition recently and will explore and experience Jerusalem’s vibrant startup ecosystem in November. Start JLM gives entrepreneurs the opportunity to connect and benefit from interaction with prominent local tech leaders in Jerusalem in a 7-day immersive […]

Motif Bio Submits NDA for iclaprim

NEW YORK, June 14, 2018 (GLOBE NEWSWIRE) — Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB), a clinical-stage biopharmaceutical company specialising in developing novel antibiotics, today announced the completion of its rolling submission of a New Drug Application (NDA) to the U.S. Food & Drug Administration (FDA) for iclaprim, a targeted, Gram-positive investigational antibiotic, for the treatment of acute bacterial skin and skin structure […]

LK-01 Granted Orphan Drug Designation by the U.S. FDA for Acute Myeloid Leukemia

BARCELONA, Spain – Leukos Biotech, a spin-off company founded by the Barcelona based Jose Carreras Leukaemia Research Institute and supported by VCF Inveready, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for LK-01, a product based on Apomorphine, for the treatment of Acute Myeloid Leukemia. Acute Myeloid Leukaemia (AML) is […]

General Data Protection Regulation (GDPR)

The new regulation for General Data Protection Regulation (GDPR) is effective as of May 25th, 2018. Any company that does not comply with the new regulation, can face significant fines. This change is one of the most important, if not THE MOST important in the field of privacy regulations in 20 years, and it effects […]